On November 18, 2026 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, reported the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
J.P. Morgan and TD Cowen are acting as the lead book-running managers for the offering. Mizuho is also acting as a book-running manager for the offering. A.G.P./Alliance Global Partners and Maxim Group LLC are acting as lead managers for the offering.
The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-294504) that was previously filed with the Securities and Exchange Commission (the "SEC") on March 20, 2026, and became automatically effective upon filing. The preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC, and a final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at View Source The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; or TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected].
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
(Press release, Sellas Life Sciences, NOV 18, 2026, View Source [SID1234674923])